On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients

  • IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
  • Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
  • The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
  • CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.

Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.

CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.

“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).

The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.

According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.

The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).

Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered